Semaglutide Helps Lose Weight but How Is Unknown

Semaglutide, marketed as Ozempic and Wegovy, is a GLP-1 receptor agonist that helps regulate appetite and blood sugar, facilitating an average 15 percent body weight reduction over 68 weeks.

However, clinical response differs greatly among patients because of complex factors like metabolic adaptation, genetics, and individual energy expenditure.

Clinical Realities of Weight Loss Medication

GLP-1 medications function by mimicking a hormone that signals fullness to the brain, effectively slowing gastric emptying and reducing appetite. While these drugs have become household names, they do not produce uniform results across the population. A University of Alberta team of experts is now studying why some people lose a lot of weight while others do not, looking at how biology and drugs interact.

How Metabolic Adaptation and Lifestyle Factors Affect GLP-1 Success

  • Metabolic Adaptation: Your body may enter an “energy-saving mode” as you lose weight, burning fewer calories than expected to maintain homeostasis; this is why weight loss often plateaus.
  • Beyond the Scale: Success with GLP-1 therapy should be measured not only by weight but by improvements in blood markers like cholesterol and glucose, as well as overall quality of life.
  • Lifestyle Synergy: Medication is most effective when paired with consistent resistance training and protein-rich nutrition, which helps preserve muscle mass and keeps your metabolism from slowing down prematurely.

How Weight Loss Lowers Resting Energy Requirements

The human body maintains energy balance through a complex system of intake and expenditure. When an individual loses weight, the total mass of fat and fat-free tissue decreases, naturally lowering the body’s resting energy requirements. Researchers are now testing whether GLP-1 therapies, which show weight loss results averaging 15 percent in clinical settings, alter these baseline metabolic processes differently across patients.

Adaptive thermogenesis serves as a biological “dimmer switch” that lowers the calories burned during resting and physical activities. A recent review of studies investigating semaglutide’s impact on energy utilization found that current evidence regarding resting energy expenditure remains neutral or inconclusive.

Because this area of semaglutide’s mechanism of action is still evolving, the University of Alberta is utilizing whole-room indirect calorimetry—a high-precision facility—to measure exactly how these medications affect calorie burning at rest and during exercise.

Factor Impact on GLP-1 Response Clinical Significance
Genetics Variable Influences individual metabolic rate
Body Composition High Loss of fat-free mass reduces calorie burn
Microbiota Emerging Potential role in nutrient absorption
Age/Sex Moderate Affects baseline metabolic demand

How Regulatory Bodies Manage Drug Access and Clinical Guidelines

The clinical efficacy of these drugs is well-documented as a pillar in obesity management, but regulatory bodies like the FDA and health authorities worldwide emphasize that these treatments require a multidisciplinary approach. Access remains tied to strict clinical guidelines, often requiring documentation of body mass index (BMI) thresholds and comorbid conditions like Type 2 diabetes or hypertension.

Researchers are currently recruiting participants with insulin resistance to observe their progress over six months. “Understanding how semaglutide influences energy use and body composition could be an important step toward explaining why individuals respond differently to weight-loss treatment,” the team said in their recent project brief. This data is vital for shifting toward personalized medicine, where clinicians can identify non-responders earlier and pivot to alternative therapeutic strategies.

When GLP-1 Receptor Agonists Are Inappropriate

GLP-1 receptor agonists are not appropriate for everyone.

Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

Germany Clinch Nations League Group With 5-0 Win Over Netherlands